Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Rick Bienkowski's Stock Ratings
Cantor Fitzgerald Analyst
Rick Bienkowski is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/04/2025
Overall Average Return
-31.6%
Smart Score
Overall Average Return Percentile
7th
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2025 | VERV | Buy Now | Verve Therapeutics | $5.27 | — | Rick Bienkowski27% | — | Upgrade | Neutral → Overweight | Get Alert |
| 03/12/2025 | BEAM | Buy Now | Beam Therapeutics | $20.31 | — | Rick Bienkowski27% | — | Reiterates | Overweight → Overweight | Get Alert |
| 01/29/2025 | BEAM | Buy Now | Beam Therapeutics | $20.31 | — | Rick Bienkowski27% | — | Upgrade | Neutral → Overweight | Get Alert |
| 12/09/2024 | LEGN | Buy Now | Legend Biotech | $33.17 | 150.23% | Rick Bienkowski27% | $83 → $83 | Reiterates | Overweight → Overweight | Get Alert |
| 11/06/2024 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 92.02% | Rick Bienkowski27% | $27 → $39 | Upgrade | Market Perform → Outperform | Get Alert |
| 09/03/2024 | ACLX | Buy Now | Arcellx | $65.55 | — | Rick Bienkowski27% | — | Initiates | → Overweight | Get Alert |
| 06/24/2024 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 606.52% | Rick Bienkowski27% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/18/2024 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 606.52% | Rick Bienkowski27% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/04/2024 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 606.52% | Rick Bienkowski27% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | LEGN | Buy Now | Legend Biotech | $33.17 | 147.21% | Rick Bienkowski27% | → $82 | Initiates | → Overweight | Get Alert |
| 11/08/2023 | CRBU | Buy Now | Caribou Biosciences | $0.87 | — | Rick Bienkowski27% | — | Initiates | → Neutral | Get Alert |
| 10/17/2023 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 57.56% | Rick Bienkowski27% | $56 → $32 | Maintains | Overweight | Get Alert |
| 09/13/2023 | VERV | Buy Now | Verve Therapeutics | $5.27 | 317.46% | Rick Bienkowski27% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 09/13/2023 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 606.52% | Rick Bienkowski27% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | EDIT | Buy Now | Editas Medicine | $1.67 | 738.47% | Rick Bienkowski27% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 09/13/2023 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 175.73% | Rick Bienkowski27% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | VERV | Buy Now | Verve Therapeutics | $5.27 | 317.46% | Rick Bienkowski27% | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 08/29/2023 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 606.52% | Rick Bienkowski27% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | EDIT | Buy Now | Editas Medicine | $1.67 | 738.47% | Rick Bienkowski27% | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 175.73% | Rick Bienkowski27% | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 606.52% | Rick Bienkowski27% | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | EDIT | Buy Now | Editas Medicine | $1.67 | 798.36% | Rick Bienkowski27% | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 02/01/2023 | VERV | Buy Now | Verve Therapeutics | $5.27 | 298.48% | Rick Bienkowski27% | → $21 | Initiates | → Neutral | Get Alert |
| 02/01/2023 | EDIT | Buy Now | Editas Medicine | $1.67 | 798.36% | Rick Bienkowski27% | → $15 | Initiates | → Overweight | Get Alert |
| 02/01/2023 | NTLA | Buy Now | Intellia Therapeutics | $9.20 | 628.26% | Rick Bienkowski27% | → $67 | Initiates | → Overweight | Get Alert |
| 02/01/2023 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 205.27% | Rick Bienkowski27% | → $62 | Initiates | → Overweight | Get Alert |
| 08/10/2022 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 456.38% | Rick Bienkowski27% | $118 → $113 | Maintains | Outperform | Get Alert |
| 08/08/2022 | CRSP | Buy Now | CRISPR Therapeutics | $38.26 | 179.67% | Rick Bienkowski27% | $112 → $107 | Maintains | Outperform | Get Alert |
| 05/10/2022 | CRSP | Buy Now | CRISPR Therapeutics | $38.26 | 192.73% | Rick Bienkowski27% | $120 → $112 | Maintains | Outperform | Get Alert |
| 05/09/2022 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 495.77% | Rick Bienkowski27% | $118 → $121 | Maintains | Outperform | Get Alert |
| 02/25/2022 | EDIT | Buy Now | Editas Medicine | $1.67 | 1517.06% | Rick Bienkowski27% | $41 → $27 | Maintains | Market Perform | Get Alert |
| 02/16/2022 | CRSP | Buy Now | CRISPR Therapeutics | $38.26 | 213.64% | Rick Bienkowski27% | $126 → $120 | Maintains | Outperform | Get Alert |
| 01/10/2022 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 495.77% | Rick Bienkowski27% | $116 → $121 | Maintains | Outperform | Get Alert |
| 11/09/2021 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 471.15% | Rick Bienkowski27% | $117 → $116 | Maintains | Outperform | Get Alert |
| 10/19/2021 | BEAM | Buy Now | Beam Therapeutics | $20.31 | 476.07% | Rick Bienkowski27% | → $117 | Initiates | → Outperform | Get Alert |
| 10/19/2021 | EDIT | Buy Now | Editas Medicine | $1.67 | 2355.53% | Rick Bienkowski27% | → $41 | Initiates | → Market Perform | Get Alert |
| 10/19/2021 | CRSP | Buy Now | CRISPR Therapeutics | $38.26 | 229.33% | Rick Bienkowski27% | → $126 | Initiates | → Outperform | Get Alert |
